» Articles » PMID: 12562506

Melatonin Increases Oestradiol-induced Bone Formation in Ovariectomized Rats

Overview
Journal J Pineal Res
Publisher Wiley
Specialty Endocrinology
Date 2003 Feb 4
PMID 12562506
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

To assess the effect of melatonin on bone metabolism in ovariectomized rats, receiving oestradiol therapy or not, melatonin was administered in the drinking water (25 microg/mL water) and oestradiol (10 microg/kg body weight) or vehicle was given subcutaneously 5 days/week for up to 60 days after surgery. Urinary deoxypyridinoline (a marker of bone resorption) and circulating levels of bone alkaline phosphatase activity (a marker of bone formation), as well as serum calcium and phosphorus levels, were measured every 15 days. Bone area (BA), bone mineral content (BMC), bone mineral density (BMD) and total body fat (expressed as 100 g body weight) were measured by dual-energy X-ray absorptiometry at the end of the experiment. Body weight and total body fat were augmented after ovariectomy, and decreased after melatonin or oestradiol treatment. The effect of melatonin on body weight was seen in sham-operated rats only. Ovariectomy augmented, and melatonin or oestradiol lowered, urinary deoxypyridinoline excretion. This effect of melatonin and oestradiol was seen mainly in ovariectomized rats. The efficacy of oestradiol to counteract ovariectomy-induced bone resorption was increased by melatonin. Melatonin or oestradiol lowered serum bone alkaline phosphatase activity. Melatonin inhibition was seen mainly on the increase of bone alkaline phosphatase activity that followed ovariectomy. Serum phosphorus levels decreased after melatonin administration and were augmented after oestradiol injection; overall, melatonin impaired the increase of serum phosphorus caused by oestradiol. Ovariectomy decreased, and oestradiol increased, serum calcium levels while melatonin augmented serum calcium in sham-operated rats only. On day 60 after surgery, BMD and content decreased after ovariectomy and were increased after oestradiol injection. Melatonin augmented BA of spine and BMC of whole of the skeleton and tibia. The highest values observed were those of rats treated concurrently with oestradiol and melatonin. The present results indicate that: (i) melatonin treatment restrained bone remodelling after ovariectomy; (ii) the effect of melatonin required adequate concentrations of oestradiol; (iii) melatonin augmented oestradiol effects on bone in ovariectomized rats; (iv) a counter-regulation by melatonin of the increase in body fat caused by ovariectomy was uncovered. The melatonin doses employed were pharmacological in terms of circulating melatonin levels but not necessarily for some other fluids or tissues.

Citing Articles

Programmed cell death and melatonin: A comprehensive review.

Rafiyian M, Reiter R, Rasooli Manesh S, Asemi R, Sharifi M, Mohammadi S Funct Integr Genomics. 2024; 24(5):169.

PMID: 39313718 DOI: 10.1007/s10142-024-01454-4.


Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study.

Altintepe Dogan S, Toker H, Goze O Biomedicines. 2024; 12(3).

PMID: 38540297 PMC: 10968284. DOI: 10.3390/biomedicines12030684.


Scoliosis school screening of 139,922 multi-ethnic children in Dali, southwestern China: A large epidemiological study.

Zhou J, Wang Y, Xie J, Zhao Z, Shi Z, Li T iScience. 2023; 26(12):108305.

PMID: 38025787 PMC: 10679892. DOI: 10.1016/j.isci.2023.108305.


The Zebrafish, an Outstanding Model for Biomedical Research in the Field of Melatonin and Human Diseases.

Aranda-Martinez P, Fernandez-Martinez J, Ramirez-Casas Y, Guerra-Librero A, Rodriguez-Santana C, Escames G Int J Mol Sci. 2022; 23(13).

PMID: 35806441 PMC: 9267299. DOI: 10.3390/ijms23137438.


Assessment of the Therapeutic Potential of Melatonin for the Treatment of Osteoporosis Through a Narrative Review of Its Signaling and Preclinical and Clinical Studies.

Zhao Y, Shao G, Liu X, Li Z Front Pharmacol. 2022; 13:866625.

PMID: 35645810 PMC: 9130700. DOI: 10.3389/fphar.2022.866625.